Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Surgery Partners (SGRY) Goodwill (2016 - 2025)

Surgery Partners (SGRY) has disclosed Goodwill for 13 consecutive years, with $5.2 billion as the latest value for Q4 2025.

  • Quarterly Goodwill rose 2.5% to $5.2 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.2 billion through Dec 2025, up 2.5% year-over-year, with the annual reading at $5.2 billion for FY2025, 2.5% up from the prior year.
  • Goodwill hit $5.2 billion in Q4 2025 for Surgery Partners, up from $5.1 billion in the prior quarter.
  • In the past five years, Goodwill ranged from a high of $5.2 billion in Q4 2025 to a low of $20.0 million in Q2 2021.
  • Historically, Goodwill has averaged $2.2 billion across 5 years, with a median of $494.8 million in 2024.
  • Biggest five-year swings in Goodwill: plummeted 99.41% in 2021 and later soared 6540.16% in 2025.
  • Year by year, Goodwill stood at $3.9 billion in 2021, then rose by 5.76% to $4.1 billion in 2022, then rose by 4.57% to $4.3 billion in 2023, then grew by 17.15% to $5.1 billion in 2024, then increased by 2.5% to $5.2 billion in 2025.
  • Business Quant data shows Goodwill for SGRY at $5.2 billion in Q4 2025, $5.1 billion in Q3 2025, and $5.1 billion in Q2 2025.